secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001725160-23-000178
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Pharmaceuticals COO Iris Roth departs effective Oct 10, 2023
---------------------------------------------------------------------

- Dr. Iris Roth ceases as COO at 11:59 p.m. ET on Oct 10, 2023.
- Company expects to provide severance benefits per Employment Agreement dated Feb 8, 2023.
- No replacement or additional details on departure reason provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000178/0001725160-23-000178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000178/zntl-20231006.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer